Clostridium difficile and the microbiota
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is the leading health care-associated illness. Both human and animal models have demonstrated the importance of the gut microbiota's capability of providing colonization resistance against C. difficile. Risk factors for disease development include antibiotic use, which disrupts the gut microbiota, leading to the loss of colonization resistance and subsequent CDI. Identification of the specific microbes capable of restoring this function remains elusive. Future studies directed at how microbial communities influence the metabolic environment may help elucidate the role of the microbiota in disease development. These findings will improve current biotherapeutics for patients with CDI, particularly those with recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These concepts of manipulating commensal–pathogen competition for nutrients, such as iron, may also prove relevant to C. difficile infection, where faecal microbial transfer has had therapeutic success through normalization of the commensal microbiota. 149 , 176”
From The battle for iron in enteric infections (2020) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Clostridium cluster XIVa (64, 76): Proteus spp.”
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
BackgroundDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421 · cited 1×
“Dethlefsen et al. found that although recovery began within weeks of ciprofloxacin cessation, the new community did not necessarily include all community members observed before antibiotic use (36).”
BackgroundDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“although compositional changes may be dependent on the antibiotic used as well as the underlying microbiota community of the individual (34, 35).”
BackgroundReduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 1×
“A decreased diversity of Firmicutes and Bacteroidetes has been observed in the microbiota of IBD patients (50).”
BackgroundLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946 · cited 1×
“These increases in CDI burden have occurred in conjunction with the emergence of hyperendemic strains (4, 5).”
BackgroundComposition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754 · cited 6×
“Using nonsequencing methods, Hopkins et al. observed that elderly patients with CDI had higher counts of Enterobacteriaceae (Proteobacteria), Enterococcus , and Lactobacillus (both Firmicutes), whereas healthy elderly patients harbored more diverse Bacteroides strains (Bacteroide-table od, fecal microbiota transplanta…”
BackgroundInfluentialThrough Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians
Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkïla, J., Monti, D., Satokari, R., Franceschi, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010667 · Cited by 1,483 · cited 1×
“The human gut microbiome undergoes extreme changes throughout life, and it is not surprising that shifts in the microbial composition have been observed in elderly people (38, 39).”
BackgroundGaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.020 · Cited by 1,452 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
BackgroundPepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128 · cited 1×
“These increases in CDI burden have occurred in conjunction with the emergence of hyperendemic strains (4, 5).”
BackgroundClostridium difficile Toxins: Mechanism of Action and Role in Disease
Voth, D. E., & Ballard, J. D. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.247-263.2005 · Cited by 1,104 · cited 1×
“These toxins, produced during the stationary phase of vegetative growth, are largely responsible for the damage to the mucosal epithelium and induction of an inflammatory response (28).”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Chang et al. observed that the microbiota community was less diverse in recurrent patients than in those with a single case of CDI, suggesting that recurrence could be predicted on the basis of the microbiota community present during infection (72).”
BackgroundSelf-citationGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003 · cited 1×
“The success rate of FMT is up to 92% in multiply recurrent CDI patients, depending on the protocol used (73).”
MethodTheriot, C. M., Koenigsknecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., Huffnagle, G. B., Z. Li, J., & Young, V. B. (2014) · Nature Communications · doi:10.1038/ncomms4114 · Cited by 974 · cited 4×
“A recent study by Theriot et al. suggests that antibiotic-induced changes that render mice susceptible to C. difficile are better reflected in terms of metabolic changes rather than changes in the microbial community composition (25).”
BackgroundResultInfluentialSelf-citationBacteria, Colonic Fermentation, and Gastrointestinal Health
Macfarlane, G. T., & Macfarlane, S. (2012) · Journal of AOAC INTERNATIONAL · doi:10.5740/jaoacint.sge_macfarlane · Cited by 970 · cited 1×
“Microbes within the gastrointestinal tract play a key role in the metabolism of bile acids (23), and it is hypothesized that the modulation of the microbiota community can impact metabolite availability.”
BackgroundAsymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935 · cited 1×
“Serum IgG antibodies against toxins A and B have been correlated with protection in human studies (89, 90).”
BackgroundEarly life antibiotic‐driven changes in microbiota enhance susceptibility to allergic asthma
Russell, S. L., Gold, M. J., Hartmann, M., Willing, B. P., Thorson, L., Wlodarska, M., Gill, N., Blanchet, M., Mohn, W. W., McNagny, K. M., et al. (2012) · The EMBO Reports · doi:10.1038/embor.2012.32 · Cited by 883 · cited 2×
“Russell et al. observed that vancomycin treatment in mice resulted in a decreased abundance of Bacteroides species in the gut, which was correlated with a decreased abundance of colonic Tregs (59).”
BackgroundKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804 · cited 1×
“One option is to treat the primary cause of disease development in CDI, toxin activity by toxins A and B. Serum IgG antibodies against toxins A and B have been correlated with protection in human studies (89, 90).”
BackgroundHALL, I. C. (1935) · American Journal of Diseases of Children · doi:10.1001/archpedi.1935.01970020105010 · Cited by 772 · cited 1×
“Introduction First identified in 1935, Clostridium difficile has become a leading cause of hospital-acquired infections (1, 2).”
BackgroundPetrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731 · cited 1×
“In humans, Petrof et al. reported successful treatment of recurrent CDI in 2 patients with a community consisting of 33 isolates from a healthy donor (94).”
BackgroundKhoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 1×
“Earlier studies using either culture-based or PCR-based methods have reported the recovery of Bacteroides species and detection of more Firmicutes in culture, only after the FMT procedure, along with successful clinical recovery (74, 75).”
MethodBuffie, C. G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., Ubeda, C., Xavier, J., & Pamer, E. G. (2012) · Infection and Immunity · doi:10.1128/iai.05496-11 · Cited by 596 · cited 1×
“Another clindamycin-based model of CDI in mice reported similar decreases in Enterobacteriaceae members, as well as differences in the recovery of the communities with and without CDI (67).”
BackgroundHopkins, M. J., Sharp, R., & Macfarlane, G. T. (2001) · Gut · doi:10.1136/gut.48.2.198 · Cited by 577
Probiotic Bacteria Reduce Salmonella Typhimurium Intestinal Colonization by Competing for Iron
Deriu, E., Liu, J. Z., Pezeshki, M., Edwards, R. A., Ochoa, R. J., Contreras, H., Libby, S. J., Fang, F. C., & Raffatellu, M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.007 · Cited by 550 · cited 1×
“Inflammatory products, such as the antimicrobial peptides lipocalin-2 and calprotectin, limit the availability of nutrients in the gut environment, potentially impacting the growth of surrounding microbes (53, 54).”
BackgroundReproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic Perturbation
Antonopoulos, D. A., Huse, S. M., Morrison, H. G., Schmidt, T. M., Sogin, M. L., & Young, V. B. (2009) · Infection and Immunity · doi:10.1128/iai.01520-08 · Cited by 550 · cited 1×
“although compositional changes may be dependent on the antibiotic used as well as the underlying microbiota community of the individual (34, 35).”
BackgroundSelf-citationRiggs, M. M., Sethi, A. K., Zabarsky, T. F., Eckstein, E. C., Jump, R. L. P., & Donskey, C. J. (2007) · Clinical Infectious Diseases · doi:10.1086/521854 · Cited by 550 · cited 1×
“difficile spores are also resistant to alcohol-based cleaners, spores are especially prevalent in hospital environments and have been detected months after initial exposure (9, 10).”
BackgroundLawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002995 · Cited by 540 · cited 1×
“Lawley et al. were able to identify a population of 6 different bacteria that were efficient at clearing CDI in mice (93).”
BackgroundRole of Clostridium difficile in antibiotic-associated pseudomembranous colitis
Bartlett, J. G., Moon, N., Chang, T. W., Taylor, N., & Onderdonk, A. B. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90457-2 · Cited by 517 · cited 1×
“Since the discovery of C. difficile as an etiological agent of antibiotic-associated diarrhea, we have come to appreciate the importance of changes in the indigenous gut microbes, collectively termed the microbiota, in the development of CDI (6).”
BackgroundKim, K. H., Fekety, R., Batts, D. H., Brown, D., Cudmore, M., Silva, J., & Waters, D. (1981) · Journal of Infectious Diseases · doi:10.1093/infdis/143.1.42 · Cited by 499 · cited 1×
“Because C. difficile spores are also resistant to alcohol-based cleaners, spores are especially prevalent in hospital environments and have been detected months after initial exposure (9, 10).”
BackgroundBACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491 · cited 1×
“Earlier studies using either culture-based or PCR-based methods have reported the recovery of Bacteroides species and detection of more Firmicutes in culture, only after the FMT procedure, along with successful clinical recovery (74, 75).”
MethodAntharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-13 · Cited by 485 · cited 1×
“Indeed, human microbiome studies of CDI have observed a decrease in butyrate-producing microbial taxa and have postulated that the abundance of microbial by-products, such as short-chain fatty acids, may be indicative of susceptibility to CDI (64, 80, 81).”
BackgroundVollaard, E. J., & Clasener, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.409 · Cited by 478 · cited 1×
“A healthy gut microbiota is necessary for protection against pathogen colonization, termed colonization resistance (32).”
BackgroundHOPKINS, M. J., & MACFARLANE, G. T. (2002) · Journal of Medical Microbiology · doi:10.1099/0022-1317-51-5-448 · Cited by 472
Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile
Britton, R. A., & Young, V. B. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.059 · Cited by 446
Self-citationWeingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423 · cited 2×
“A recent study by Weingarden et al. observed high concentrations of primary bile acids in patients with recurrent CDI (27).”
BackgroundClostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance
Gerding, D. N., Johnson, S., Rupnik, M., & Aktories, K. (2014) · Gut Microbes · doi:10.4161/gmic.26854 · Cited by 416
Epidemiology of Community-Associated Clostridium difficile Infection, 2009 Through 2011
Chitnis, A. S., Holzbauer, S. M., Belflower, R. M., Winston, L. G., Bamberg, W. M., Lyons, C., Farley, M. M., Dumyati, G. K., Wilson, L. E., Beldavs, Z. G., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7056 · Cited by 405
Nguyen, G. C., Kaplan, G. G., Harris, M. L., & Brant, S. R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01780.x · Cited by 401 · cited 1×
“Inflammatory bowel disease (IBD) has been linked to more severe disease outcome and is increasingly found to be a risk factor for CDI (48, 49).”
BackgroundPrimary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea
Shim, J. K., Johnson, S., Samore, M. H., Bliss, D. Z., & Gerding, D. N. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08062-8 · Cited by 391 · cited 1×
“The observation that asymptomatically colonized patients have a reduced risk of developing CDI has prompted research into using nontoxigenic strains as preventative therapy against C. difficile (95).”
BackgroundClostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352 · cited 1×
“First identified in 1935, Clostridium difficile has become a leading cause of hospital-acquired infections (1, 2).”
BackgroundLawley, T. D., Clare, S., Walker, A. W., Goulding, D., Stabler, R. A., Croucher, N., Mastroeni, P., Scott, P., Raisen, C., Mottram, L., et al. (2009) · Infection and Immunity · doi:10.1128/iai.00558-09 · Cited by 349
Young, V. B., & Schmidt, T. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.3.1203-1206.2004 · Cited by 335 · cited 1×
“Indeed, human microbiome studies of CDI have observed a decrease in butyrate-producing microbial taxa and have postulated that the abundance of microbial by-products, such as short-chain fatty acids, may be indicative of susceptibility to CDI (64, 80, 81).”
BackgroundSelf-citationAntibiotic-Associated Diarrhea: Epidemiology, Trends and Treatment
McFarland, L. V. (2008) · Future Microbiology · doi:10.2217/17460913.3.5.563 · Cited by 333 · cited 1×
“The classes of anti-biotics associated with development of CDI include clindamycin, cephalosporins, and penicillins (37).”
BackgroundSorg, J. A., & Sonenshein, A. L. (2010) · Journal of Bacteriology · doi:10.1128/jb.00610-10 · Cited by 332 · cited 2×
“These results are in agreement with the in vitro and in vivo mouse studies that have previously observed that secondary bile acids, such as lithocholic or deoxycholic acid, inhibit C. difficile growth (20, 25).”
BackgroundResultRecovery of the Gut Microbiome following Fecal Microbiota Transplantation
Seekatz, A. M., Aas, J., Gessert, C. E., Rubin, T. A., Saman, D. M., Bakken, J. S., & Young, V. B. (2014) · mBio · doi:10.1128/mbio.00893-14 · Cited by 331 · cited 1×
“Although the bacterial community is responsible for producing the metabolic environment, it is possible that several types of bacterial communities with similar functions may be capable of the same metabolic outcome, and that structure alone may not be enough to determine recurrence risk (82).”
BackgroundSelf-citationAngelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330 · cited 1×
“…generally found at high levels within patients with active CDI, decreases after FMT. Interestingly, the dominant donor microbes classified at either at the genus level or the operational unit level are observed to be prevalent within the recipient for only days following FMT (77, 79).”
BackgroundSchubert, A. M., Rogers, M. A. M., Ring, C., Mogle, J., Petrosino, J. P., Young, V. B., Aronoff, D. M., & Schloss, P. D. (2014) · mBio · doi:10.1128/mbio.01021-14 · Cited by 318 · cited 7×
“Using nonsequencing methods, Hopkins et al. observed that elderly patients with CDI had higher counts of Enterobacteriaceae (Proteobacteria), Enterococcus , and Lactobacillus (both Firmicutes), whereas healthy elderly patients harbored more diverse Bacteroides strains (Bacteroide-table od, fecal microbiota transplanta…”
ResultInfluentialSelf-citationRole of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315 · cited 1×
“Additionally, the microbiota of patients with IBD has been associated with the presence of multiple potentially pathogenic bacteria, mainly within the Proteobacteria phylum (51, 52).”
BackgroundHamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315 · cited 4×
“Interestingly, the dominant donor microbes classified at either at the genus level or the operational taxonomic unit level are observed to be prevalent within the recipient for only days following FMT (77, 79).”
BackgroundInfluentialJohnson, S., Schriever, C., Galang, M., Kelly, C. P., & Gerding, D. N. (2007) · Clinical Infectious Diseases · doi:10.1086/511870 · Cited by 312 · cited 1×
“Antibiotics other than vancomycin or metronidazole, such as fidaxomicin, tigecycline, and rifampicin, have been used to treat severe or recurrent CDI (83, 84).”
BackgroundReeves, A. E., Koenigsknecht, M. J., Bergin, I. L., & Young, V. B. (2012) · Infection and Immunity · doi:10.1128/iai.00647-12 · Cited by 292 · cited 1×
“difficile colonization and less severe disease (69).”
Self-citationBacteriotherapy for chronic relapsing Clostridium difficile in six patients
Tvede, M. (1989) · The Lancet · Cited by 290
Reeves, A. E., Theriot, C. M., Bergin, I. L., Huffnagle, G. B., Schloss, P. D., & Young, V. B. (2011) · Gut Microbes · doi:10.4161/gmic.2.3.16333 · Cited by 270 · cited 1×
“Reeves et al. found that susceptible mice were dominated by Lactobacillaceae and Enterobacteriaceae families before infection following treatment with cefoperazone, clindamycin, or a multi-antibiotic cocktail (68).”
BackgroundSelf-citationThe distribution of Clostridium difficile in the environment of South Wales
Al Saif, N., & BRAZIER, J. S. (1996) · Journal of Medical Microbiology · doi:10.1099/00222615-45-2-133 · Cited by 259
Clostridium difficile Infection in Infants and Children
COMMITTEE ON INFECTIOUS DISEASES, Schutze, G. E., Willoughby, R. E., Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Glode, M. P., Jackson, M. A., Keyserling, H. L., et al. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2992 · Cited by 256
Pepin, J., Routhier, S., Gagnon, S., & Brazeau, I. (2006) · Clinical Infectious Diseases · doi:10.1086/501126 · Cited by 246 · cited 1×
“Recurrence is estimated to occur in 20%–30% of CDI patients; after each incidence, the chance of recurrence increases (70).”
BackgroundAronsson, B., Mollby, R., & Nord, C. E. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.3.476 · Cited by 245 · cited 1×
“Considering these observations, it is not surprising that the rate of CDI is higher for people ages 65 and over and accounts for the majority of diarrheal cases in long-term living facilities (41–43).”
BackgroundBritton, R. A., & Young, V. B. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.04.001 · Cited by 240 · cited 1×
“An undisrupted microbiota is capable of resisting colonization by pathogens, and multiple mechanisms have been suggested for why disruption of the microbiota leads to loss of colonization resistance, including competition for nutrients, ecological competition, and niche exclusion (33).”
BackgroundSelf-citationC. difficile Infection: Changing Epidemiology and Management Paradigms
Vindigni, S. M., & Surawicz, C. M. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.24 · Cited by 234
Rea, M. C., O'Sullivan, O., Shanahan, F., O'Toole, P. W., Stanton, C., Ross, R. P., & Hill, C. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.05176-11 · Cited by 222 · cited 1×
“While some studies comparing non-CDI and CDI samples have included secondary recurrent samples in their analysis, none were able to identify particular aspects unique to patients with recurrent CDI (63).”
ResultDial, S. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060284 · Cited by 218 · cited 1×
“The use of proton pump inhibitors (PPIs), particularly in conjunction with antibiotics, has been correlated with higher CDI incidence in some studies (44, 45).”
BackgroundClostridium difficile in Long-Term–Care Facilities for the Elderly
Simor, A. E., Bradley, S. F., Strausbaugh, L. J., Crossley, K., Nicolle, L. E., & SHEA Long-Term–Care Committee (2002) · Infection Control & Hospital Epidemiology · doi:10.1086/501997 · Cited by 218
Chenodeoxycholate Is an Inhibitor of Clostridium difficile Spore Germination
Sorg, J. A., & Sonenshein, A. L. (2009) · Journal of Bacteriology · doi:10.1128/jb.01260-08 · Cited by 199 · cited 1×
“Conversely, other secondary bile acids, such as chenodeoxycholate, inhibit the germination of C. difficile spores (22).”
BackgroundOhkusa, T., Sato, N., Ogihara, T., Morita, K., Ogawa, M., & Okayasu, I. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02834.x · Cited by 198 · cited 1×
“Additionally, the microbiota of patients with IBD has been associated with the presence of multiple potentially pathogenic bacteria, mainly within the Proteobacteria phylum (51, 52).”
BackgroundEglow, R., Pothoulakis, C., Itzkowitz, S., Israel, E. J., O'Keane, C. J., Gong, D., Gao, N., Xu, Y. L., Walker, W. A., & LaMont, J. T. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115957 · Cited by 197 · cited 1×
“It has been postulated that infants may lack the receptor necessary for disease development (18) or that compounds in human breast milk, such as maternal IgA, may prevent toxin binding (19).”
BackgroundRousseau, C., Poilane, I., De Pontual, L., Maherault, A.-C., Le Monnier, A., & Collignon, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis637 · Cited by 196 · cited 3×
“Thus, the microbiota can provide functions the host alone cannot supply, such as the breakdown of essential nutrients, drug metabolism, immune development, and pathogen resistance (7).”
BackgroundMetabolism of Bile Salts in Mice Influences Spore Germination in Clostridium difficile
Giel, J. L., Sorg, J. A., Sonenshein, A. L., & Zhu, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008740 · Cited by 194 · cited 1×
“Indeed, in vitro studies have shown that PPIs can affect the growth of Lactobacillus , a common resident of the mouth and gut (47). levels of bile salts and promoted spore germination, while cecal extracts from untreated mice did not (24).”
BackgroundLouie, T. J., Emery, J., Krulicki, W., Byrne, B., & Mah, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-07 · Cited by 190
Fuentes, S., van Nood, E., Tims, S., Heikamp-de Jong, I., ter Braak, C. J. F., Keller, J. J., Zoetendal, E. G., & de Vos, W. M. (2014) · The ISME Journal · doi:10.1038/ismej.2014.13 · Cited by 175 · cited 1×
“Indeed, human microbiome studies of CDI have observed a decrease in butyrate-producing microbial taxa and have postulated that the abundance of microbial by-products, such as short-chain fatty acids, may be indicative of susceptibility to CDI (64, 80, 81).”
BackgroundSong, Y., Garg, S., Girotra, M., Maddox, C., von Rosenvinge, E. C., Dutta, A., Dutta, S., & Fricke, W. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081330 · Cited by 172 · cited 2×
“Lachnospiraceae (77, 78) Verrucomicrobia (27)”
Underwood, S., Guan, S., Vijayasubhash, V., Baines, S. D., Graham, L., Lewis, R. J., Wilcox, M. H., & Stephenson, K. (2009) · Journal of Bacteriology · doi:10.1128/jb.00882-09 · Cited by 165 · cited 1×
“These spores can survive even in harsh environmental conditions (8).”
BackgroundManges, A. R., Labbe, A., Loo, V. G., Atherton, J. K., Behr, M. A., Masson, L., Tellis, P. A., & Brousseau, R. (2010) · The Journal of Infectious Diseases · doi:10.1086/657319 · Cited by 149
Clostridium difficile Infection in the Inflammatory Bowel Disease Patient
Berg, A. M., Kelly, C. P., & Farraye, F. A. (2013) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22964 · Cited by 146 · cited 1×
“Inflammatory bowel disease (IBD) has been linked to more severe disease outcome and is increasingly found to be a risk factor for CDI (48, 49).”
BackgroundThe Effect of Proton Pump Inhibitors on the Human Microbiota
Vesper, B., Jawdi, A., Altman, K., Haines III, G., Tao, L., & Radosevich, J. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048392 · Cited by 145 · cited 1×
“It is hypothesized that PPIs, which generally increase the pH of the stomach, may affect other gastrointestinal sites and are thus capable of modulating the microbiota (46).”
BackgroundRousseau, C., Levenez, F., Fouqueray, C., Doré, J., Collignon, A., & Lepage, P. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01507-10 · Cited by 138 · cited 2×
“The infant microbiome is distinct from adults’, and differences in the microbiome may be important in both colonization and disease resistance (16, 17).”
BackgroundHeeg, D., Burns, D. A., Cartman, S. T., & Minton, N. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032381 · Cited by 111 · cited 1×
“In vitro studies indicate that germination and outgrowth into the vegetative form depends on the presence of specific primary bile acids, such as taurocholate (20, 21).”
BackgroundVillano, S. A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E., & Gerding, D. N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00913-12 · Cited by 107 · cited 1×
“Nontoxigenic strains have also been used safely in studies of volunteer patients in prevention of recurrent C. difficile (97).”
BackgroundA New Strategy for the Prevention of Clostridium difficile Infection
Howerton, A., Patra, M., & Abel‐Santos, E. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit068 · Cited by 103
The impact of intestinal inflammation on the nutritional environment of the gut microbiota
Faber, F., & Bäumler, A. J. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.04.014 · Cited by 93 · cited 1×
“Inflammatory products, such as the antimicrobial peptides lipocalin-2 and calprotectin, limit the availability of nutrients in the gut environment, potentially impacting the growth of surrounding microbes (53, 54).”
BackgroundGoldenberg, S. D., & French, G. L. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.03.001 · Cited by 88 · cited 1×
“difficile binary toxin (CDT), has been observed to disrupt the actin cytoskeleton, and some studies suggest its presence may increase strain virulence (29, 30); however, its presence does not always correlate with disease severity (31).”
BackgroundClostridium difficile Infection in the Elderly
Keller, J. M., & Surawicz, C. M. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.10.008 · Cited by 84
Antimicrobial Use and Risk for Recurrent Clostridium difficile Infection
Drekonja, D. M., Amundson, W. H., DeCarolis, D. D., Kuskowski, M. A., Lederle, F. A., & Johnson, J. R. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.05.032 · Cited by 78 · cited 1×
“Although it is unknown why recurrence occurs in some patients and not others, risk factors for recurrent CDI include the use of non-CDI antibiotics following an initial episode, as well as increased age and disease severity (71).”
BackgroundManagement of Clostridium difficile Infection: Thinking Inside and Outside the Box
Gerding, D. N., & Johnson, S. (2010) · Clinical Infectious Diseases · doi:10.1086/657116 · Cited by 77 · cited 1×
“Both passive and active immunization strategies against toxins have been explored as potential methods to treat C. difficile (91).”
BackgroundNagaro, K. J., Phillips, S. T., Cheknis, A. K., Sambol, S. P., Zukowski, W. E., Johnson, S., & Gerding, D. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00580-13 · Cited by 75 · cited 1×
“Recently, Nagaro et al. observed that hamsters infected with nontoxigenic strains were protected from infection with the hyperendemic BI/NAP1/027 strain, which is usually 100% fatal in hamsters (96).”
BackgroundGut Microbiota Patterns Associated with Colonization of Different Clostridium difficile Ribotypes
Skraban, J., Dzeroski, S., Zenko, B., Mongus, D., Gangl, S., & Rupnik, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058005 · Cited by 70
Stratification and compartmentalisation of immunoglobulin responses to commensal intestinal microbes
Macpherson, A. J., & McCoy, K. D. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.09.004 · Cited by 70 · cited 1×
“The type of gut community can potentially affect the resident mucosal IgA repertoire (55), and a reduction in IgA-producing cells has been observed in colonic biopsies of patients with recurrent disease (56).”
BackgroundTigecycline for the Treatment of Severe Clostridium difficile Infection
Larson, K. C., Belliveau, P. P., & Spooner, L. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q080 · Cited by 70 · cited 1×
“been observed to inhibit toxin production and growth in mice and has been used to treat severe disease in humans (86, 87).”
BackgroundBassis, C. M., Theriot, C. M., & Young, V. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02262-13 · Cited by 67 · cited 1×
“difficile are able to change the microbiota, potentially resulting in a loss of colonization resistance (88).”
BackgroundSelf-citationJohal, S. S., Lambert, C. P., Hammond, J., James, P. D., Borriello, S. P., & Mahida, Y. R. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015875 · Cited by 62 · cited 1×
“The type of gut community can potentially affect the resident mucosal IgA repertoire (55), and a reduction in IgA-producing cells has been observed in colonic biopsies of patients with recurrent disease (56).”
BackgroundRolfe, R. D., & Song, W. (1995) · Journal of Medical Microbiology · doi:10.1099/00222615-42-1-10 · Cited by 52 · cited 1×
“It has been postulated that infants may lack the receptor necessary for disease development (18) or that compounds in human breast milk, such as maternal IgA, may prevent toxin binding (19).”
BackgroundJump, R. L. P., Li, Y., Pultz, M. J., Kypriotakis, G., & Donskey, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00839-10 · Cited by 45 · cited 1×
“been observed to inhibit toxin production and growth in mice and has been used to treat severe disease in humans (86, 87).”
BackgroundClostridium difficile infection: The scope of the problem
Dubberke, E. (2012) · Journal of Hospital Medicine · doi:10.1002/jhm.1916 · Cited by 44 · cited 1×
“Within the US, an estimated 14,000 deaths are attributed to C. difficile infection (CDI) annually, with associated costs between $1 billion and $3 billion (3).”
BackgroundBaines, S. D., Freeman, J., & Wilcox, M. H. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01085-08 · Cited by 44 · cited 1×
“Drugs that bind toxin in vitro, such as tolevamer, have also been used in human trials, but with limited success (92).”
MethodHeterogeneity ofClostridium difficile isolates from infants
Collignon, A., Ticchi, L., Depitre, C., Gaudelus, J., Delmée, M., & Corthier, G. (1993) · European Journal of Pediatrics · doi:10.1007/bf01956743 · Cited by 39 · cited 1×
“Another potential reservoir of C. difficile resides in the infant population, in which colonization is estimated to occur in up to 45% of individuals (14, 15).”
BackgroundJohnson, S., & Gerding, D. N. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis833 · Cited by 36 · cited 1×
“Antibiotics other than vancomycin or metronidazole, such as fidaxomicin, tigecycline, and rifampicin, have been used to treat severe or recurrent CDI (83, 84).”
BackgroundEffect of Proton Pump Inhibitor Pantoprazole on Growth and Morphology of Oral Lactobacillus Strains
Altman, K. W., Chhaya, V., Hammer, N. D., Pavlova, S. I., Vesper, B. J., Tao, L., & Radosevich, J. A. (2008) · The Laryngoscope · doi:10.1097/mlg.0b013e318161f9bf · Cited by 24 · cited 1×
“Indeed, in vitro studies have shown that PPIs can affect the growth of Lactobacillus , a common resident of the mouth and gut (47). levels of bile salts and promoted spore germination, while cecal extracts from untreated mice did not (24).”
BackgroundStewart, D. B., Berg, A. S., & Hegarty, J. P. (2013) · Annals of Surgery · doi:10.1097/sla.0000000000000469 · Cited by 19
Diverse Sources of C. difficile Infection
Eyre, D. W., Wilcox, M. H., & Walker, A. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1313601 · Cited by 12 · cited 1×
“A recent molecular epidemiological study by Eyre et al. that used whole-genome sequencing to track exposure and transmission of C. difficile concluded that one-third of CDI cases were not associated with the hospital (12).”
Background
Cited by
Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes
Bordenstein, S. R., & Theis, K. R. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002226 · Cited by 1,240
Mechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
“Dysbiosis can trigger disease in the first weeks of life as observed in necrotizing enterocolitis [14], during adulthood through the promotion of colorectal cancer [15], or in elderly people as exemplified by Clostridium difficile-associated diarrhea [16].”
BackgroundAntibiotics in early life and obesity
Cox, L. M., & Blaser, M. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.210 · Cited by 541
Regional Diversity of the Gastrointestinal Microbiome
Martinez-Guryn, K., Leone, V., & Chang, E. B. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.011 · Cited by 465
“difficile has been observed at low levels in healthy humans, particularly infants, antibiotic-induced disruption of the indigenous colonic microbiota and resulting increases in colonic primary bile acid concentrations promote its outgrowth, toxin production, and invasion (Seekatz and Young, 2014).”
BackgroundCurrent Sampling Methods for Gut Microbiota: A Call for More Precise Devices
Tang, Q., Jin, G., Wang, G., Liu, T., Liu, X., Wang, B., & Cao, H. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00151 · Cited by 455
Metadata
- Authors
- Seekatz, A. M., & Young, V. B.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Young, Vincent B.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-18
- Volume
- 124
- Issue
- 10
- Pages
- 4182-4189
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4191019
- OpenAlex
- W2020298266
- Cited by
- 255
- References
- 100
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 17 · 2020: 31 · 2019: 23 · 2018: 28 · 2017: 28 · 2016: 19 · 2015: 13 · 2014: 4
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Michigan (48109)
- National Institutes of Health
- College of Pharmacy, University of Michigan
- Medical School, University of Michigan
- National Institute of Allergy and Infectious Diseases (U19AI090871)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, colonization resistance, antibiotic-induced dysbiosis, recurrent Clostridium difficile infection, biologic therapy, nosocomial infections
- MeSH terms
- Age Factors, Aged, Animals, Clostridium Infections, Humans, Immune System, Recurrence, Risk Factors, Spores, Bacterial, Clostridioides difficile, Gastrointestinal Tract, Mice, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.